Journal articles: 'Interleukines 10'

1

Buxeraud, Jacques. "Ilaris®, inhibiteur des interleukines." Actualités Pharmaceutiques 49, no. 500 (November 2010): 15–16. http://dx.doi.org/10.1016/s0515-3700(10)70796-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Buxeraud, Jacques. "Stelara®, antipsoriasique inhibiteur des interleukines." Actualités Pharmaceutiques 49, no. 498 (September 2010): 11–12. http://dx.doi.org/10.1016/s0515-3700(10)70743-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ungureanu, Aurelian, Myrto Costopoulos, Magali Le Garff-Tavernier, Timothée Parratte, Remy Hurstel, Claude Gaultier, and Guido Ahle. "Lésion inflammatoire pseudotumorale ou lymphome cérébral ? L’intérêt du dosage des interleukines 6/10 dans le LCR." Revue Neurologique 174 (April 2018): S152—S153. http://dx.doi.org/10.1016/j.neurol.2018.01.351.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Maier, Bernd, Karsten Schwerdtfeger, Angelika Mautes, Miron Holanda, Martin Müller, Wolf Ingo Steudel, and Ingo Marzi. "DIFFERENTIAL RELEASE OF INTERLEUKINES 6, 8, AND 10 IN CEREBROSPINAL FLUID AND PLASMA AFTER TRAUMATIC BRAIN INJURY." Shock 15, no. 6 (June 2001): 421–26. http://dx.doi.org/10.1097/00024382-200115060-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Gantsev, Shamil Kh, and R. R. Bakiyev. "Local tissue interleukine profile in breast cancer." Russian Journal of Oncology 21, no. 1-2 (April 15, 2016): 60–65. http://dx.doi.org/10.18821/1028-9984-2015-21-1-60-65.

Full text

Abstract:

Breast cancer ranks first in the structure of oncological diseases in women in Russia and in the World. In recent years there have been numerous reports that the growth and progression of breast cancer and other tumors depend not only on their malignant potential, but also on stromal factors presented in the tumor microenvironment and intercellular interactions. The aim of our study was to evaluate intercellular interactions of the tissues surrounding the tumor, by means of determination of the locally interleukine profile. We have identified interleukine profiles of the axillary fatty tissue from the lesions and subcutaneous fat of the anterior chest wall, located at a maximum distance from the tumors, in stage IIa-IIIb breast cancer patients. As a result we came to a conclusion: the method based on the measurement of IL-1, IL-2, IL-6, IL-10 and а-TNF levels in the tissues and in the blood allows to evaluate the immune processes occurring in the tissues surrounding the tumor; adipose tissue of various areas of breast cancer patients differs significantly according to the level of interleukines, which indicates that different involvement of adipose tissue in various areas of the immune response; there is a dependence of the local immune status of armpit adipose tissue on the expression of ER, PgR, Her2/neu on the surface of breast cancer cells.

APA, Harvard, Vancouver, ISO, and other styles

6

Jordan, Iolanda, Mònica Balaguer, M. Esther Esteban, Francisco José Cambra, Aida Felipe, Lluïsa Hernández, Laia Alsina, Marta Molero, Miquel Villaronga, and Elisabeth Esteban. "Glutamine effects on heat shock protein 70 and interleukines 6 and 10: Randomized trial of glutamine supplementation versus standard parenteral nutrition in critically ill children." Clinical Nutrition 35, no. 1 (February 2016): 34–40. http://dx.doi.org/10.1016/j.clnu.2015.01.019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ducloie, Mathilde, Natalia Shor, Remi Bertinchamp, François Le Pelletier, Magali Le Garff-Tavernier, Caroline Houillier, and Mehdi Touat. "Apport du profil cytokinique des interleukines 6 et 10 dans le LCR et de la biopsie cutanée dans le diagnostic précoce d’un lymphome intravasculaire (LIV) se présentant sous la forme d’une myélite subaiguë." Revue Neurologique 177 (April 2021): S39. http://dx.doi.org/10.1016/j.neurol.2021.02.165.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Linta, L. S. O., P. Gouthon, T. Hountohotegbe, F. Messan, B. K. Nouatin, J. P. Kouassi, and A. Bigot. "Réponses inflammatoires au cours d’une série de matchs chez des handballeurs de l’élite en République du Bénin." International Journal of Biological and Chemical Sciences 14, no. 4 (August 17, 2020): 1354–66. http://dx.doi.org/10.4314/ijbcs.v14i4.15.

Full text

Abstract:

Les données liées aux réponses inflammatoires en situation de match chez les handballeurs qui pratiquent dans un environnement immunostimulant comme celui du Bénin, ne sont pas disponibles. Cette étude avait pour objectif de déterminer chez des handballeurs appartenant à l’élite du Bénin, les modifications des paramètres associés à la réponse inflammatoire, induites par une série de trois matchs expérimentaux. Il s’agit d’une étude d’intervention, entreprise avec 16 joueurs juniors (JJ) et seniors (JS), répartis de façon aléatoire en deux équipes A et B, qui se sont affrontées pendant ces matchs. La numération des leucocytes circulants a été déterminée, les interleukines Il-6, Il-10 et le tumor necrosis factor (TNF-α) ont été dosés avant, juste à la fin, puis 24 heures après le premier (Match 1) et le troisième (Match 3) matchs. Les accroissements des moyennes des leucocytes totaux, des neutrophiles, de l’IL-6, de l’IL-10 et du TNF-α enregistrés au cours du troisième match étaient plus importants (p ˂ 0,05) que ceux observés à la fin du premier. Après 24 heures de récupération, la restauration des lymphocytes était de 83,3%, celle des leucocytes totaux de 76,6%, celle des neutrophiles de 57,7%, celles du TNF-α, de l’IL-6, de l’IL-10, respectivement de 61,3%, 64,0% et 57,2%. La série de trois matchs a eu un effet cumulatif sur l’augmentation des moyennes des paramètres étudiés et la récupération 24 h après le dernier match n’a atteint 100% pour aucun d’eux. Il est donc impérieux que des travaux soient réalisés à brève échéance, pour déterminer la méthode d’entraînement qui induit à la fois le développement des capacités physiques et la récupération rapide du système immunitaire en période d’entraînement et de compétition chez ces joueurs.Mots clés : Leucocytes, cytokines, compétition, Afrique subsaharienne. English Title: Inflammatory responses during a series of matches among elite handball players in BeninData related to inflammatory responses in match situations among handball players who practice in an immunostimulating environment such as the one in the Republic of Benin are not available. The aim of this study was to determine among elite male handball players, the changes in the parameters associated with the inflammatory response, induced by a series of three experimental matches. This research was an intervention study, undertaken with 16 junior (JP) and senior (SP) players, randomly assigned to two teams A and B for the experimental matches. Circulating leukocyte counts were determined, interleukins Il-6, Il-10, and tumor necrosis factor (TNF-α) were measured before, just at the end, and 24 hours after the first (Match 1) and the third (Match 3) matches. The increases in the averages of total leukocyte, neutrophil counts, the IL-6, IL-10 and TNF-α concentrations recorded during the third match were greater (p ˂ 0.05) than those observed at the end of the first. After 24 hours from the end, lymphocyte recovery was 83.3%, total leukocyte counts recovery was 76.6%, that of neutrophils was 57.7%. The TNF-α, IL-6 and IL-10 concentrations were respectively restored at 61.3%, 64.0%, and 57.2%. The three-match series had a cumulative effect on the increase in the mean values of the parameters studied. The 24 hours recovery following the last match was insufficient for 100% restoration of the inflammatory response makers. Therefore, it is imperative to carry out studies to determine a training method that induces both development of physical capacities and rapid recovery of the immune system during training sessions’ and competitions’ in these players.Keywords: Leukocytes, cytokines, competition, sub-Saharan Africa.

APA, Harvard, Vancouver, ISO, and other styles

9

&NA;. "Interleukin-10." Drugs in R & D 1, no. 3 (January 1999): 262–64. http://dx.doi.org/10.2165/00126839-199901030-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Goldman, Michel, Thierry Velu, and Marina Pretolani. "Interleukin-10." BioDrugs 7, no. 1 (January 1997): 6–14. http://dx.doi.org/10.2165/00063030-199707010-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

DEWAALMALEFYT, R., M. RONCAROLO, H. SPITS, and J. DEVRIES. "Interleukin-10." Current Opinion in Immunology 4, no. 3 (June 1992): 314–20. http://dx.doi.org/10.1016/0952-7915(92)90082-p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Asadullah, K., R. Sabat, M. Friedrich, W. Docke, H. Volk, and W. Sterry. "Interleukin-10." Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 5, no. 3 (August 1, 2006): 223–31. http://dx.doi.org/10.2174/187152306778017700.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Moore, K. W., A. O'Garra, R. W. Malefyt, P. Vieira, and T. R. Mosmann. "Interleukin-10." Annual Review of Immunology 11, no. 1 (April 1993): 165–90. http://dx.doi.org/10.1146/annurev.iy.11.040193.001121.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Klava, Andrew. "Interleukin-10." Archives of Surgery 132, no. 4 (April 1, 1997): 425. http://dx.doi.org/10.1001/archsurg.1997.01430280099016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Umetsu, Dale T., and Rosemarie H. DeKruyff. "Interleukin-10." American Journal of Respiratory Cell and Molecular Biology 21, no. 5 (November 1999): 562–63. http://dx.doi.org/10.1165/ajrcmb.21.5.f171.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Parsons, Polly E. "Interleukin-10." Critical Care Medicine 26, no. 5 (May 1998): 818–19. http://dx.doi.org/10.1097/00003246-199805000-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Zlotnik, Albert, and Kevin W. Moore. "Interleukin 10." Cytokine 3, no. 5 (September 1991): 366–71. http://dx.doi.org/10.1016/1043-4666(91)90039-g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Stumhofer, Jason S., Jonathan S. Silver, Arian Laurence, Paige M. Porrett, Tajie H. Harris, Laurence A. Turka, Matthias Ernst, Christiaan J. M. Saris, John J. O'Shea, and Christopher A. Hunter. "Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10." Nature Immunology 8, no. 12 (November 11, 2007): 1363–71. http://dx.doi.org/10.1038/ni1537.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Masood, Aetsam, Mahmood Kayani, and Sajida Batool. "Targetting Interleukins Involved in Glioblastoma – A New Pharmacological Approach." Journal of Life and Bio Sciences Research 1, no. 3 (December 14, 2020): 82–88. http://dx.doi.org/10.38094/jlbsr1330.

Full text

Abstract:

Brain tumor is unchecked growth of brain cells disrupting many of its important functions and, affecting molecular regulatory and signaling networks. Glioblastoma is one of the most deleterious tumors of human brain. Cytokines are secondary messenger molecules in many of the immunological and other biochemical reactions. With glioblastoma progression, various cytokines are secreted that either up-regulate or down-regulate many others with immunological function. Interleukins are a family of cytokines acting mainly as immune-regulatory proteins. They have been implicated in brain tumor initiation, progression and invasion. Due to their multiple and varied regulatory roles at every stage of tumor, they are now becoming an attractive target for study in glioblastoma. This mini review briefly summarizes the types and roles of major interleukins and their regulation and, effects in glioblastoma that have been studied so far. Immunotherapeutic aspects are particularly emphasized as the promising therapeutic targets to control brain tumors. Main types of interleukins which are implicated in brain tumors are discussed here which includes interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), and interleukin-12 (IL-12). Glioblastoma is one of the most invasive tumor and still lack effective control measures clinically. Conventional treatments like chemotherapy and radiation therapy are not only ineffective in controlling the spread of glioblastoma, but also have damaging and unwanted side effects on healthy cells. Immunotherapy by blocking and/or increasing the action of certain interleukins has proven to be effective control measure in laboratory investigations. Future work extending these findings to clinical and human trials is expected to provide effective treatment measures.

APA, Harvard, Vancouver, ISO, and other styles

20

Reineke, Ulrich, Robert Sabat, Hans-Dieter Volk, and Jens Schneider-Mergener. "Mapping of the interleukin-10/interleukin-10 receptor combining site." Protein Science 7, no. 4 (April 1998): 951–60. http://dx.doi.org/10.1002/pro.5560070412.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Mittal, Sharad K., Kyung-Jin Cho, Satoshi Ishido, and Paul A. Roche. "Interleukin 10 (IL-10)-mediated Immunosuppression." Journal of Biological Chemistry 290, no. 45 (September 25, 2015): 27158–67. http://dx.doi.org/10.1074/jbc.m115.682708.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Lagha, A., S. Zidi, M. Stayoussef, E. Gazouani, R. Kochkar, S. Kochbati, W. Y. Almawi, and B. Yacoubi-Loueslati. "Interleukin-1β, Interleukin1-Ra, Interleukin-10, and tumor necrosis factor-α polymorphisms in Tunisian patients with rheumatoid arthritis." Pathologie Biologie 63, no. 4-5 (September 2015): 179–84. http://dx.doi.org/10.1016/j.patbio.2015.04.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Shah, Neil, Jochen Kammermeier, Mamoun Elawad, and Erik-Oliver Glocker. "Interleukin-10 and Interleukin-10–Receptor Defects in Inflammatory Bowel Disease." Current Allergy and Asthma Reports 12, no. 5 (August 14, 2012): 373–79. http://dx.doi.org/10.1007/s11882-012-0286-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Bazri, Elahe, Sirous Khorram, Mehran Mesgari, Mohammad Asghari-jafarabadi, Ali Tarighat-Esfanjani, and Yalda Salari. "Synergistic Effects of Nano-Sized Clinoptilolite and Nigella Sativa on Inflammatory and Hematological Factors in Rats with Type 2 Diabetes." Journal of Molecular Biology Research 9, no. 1 (January 21, 2019): 7. http://dx.doi.org/10.5539/jmbr.v9n1p7.

Full text

Abstract:

The inflammatory efficacy of supplementation of natural nano-sized clinoptilolite (NCLN) and Nigella sativa (NS) was evaluated At the end of 7th week in interleukin1β (IL1β), interleukin10 (IL-10), interleukin6 (IL-6) and platelet (PLT), white blood cell (WBC), red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV). 42 rats were divided into two groups as diabetic and non-diabetic. Diabetic group divided into 4 subgroups as normal control (NC), NS 1% food, NCLN 2%/food, NS 1%/food + NCLN 2%/food and fed high fat diet (HFD) for 1 month, then injected 35mg/kg BW STZ to induce type 2 diabetes (T2D). Our results showed IL-10 in NCLN and NCLN+NS groups were significantly higher NC group (p<0.05). IL-6 decreased in NS group in comparison with DC group. And PLT decreased significantly in NCLN group in comparison with other groups. Our data suggests NS and NCLN may have synergistic beneficial effects on increasing some of anti-inflammatory factors.

APA, Harvard, Vancouver, ISO, and other styles

25

Holland, Gina, and Albert Zlotnik. "Interleukin-10 and Cancer." Cancer Investigation 11, no. 6 (January 1993): 751–58. http://dx.doi.org/10.3109/07357909309046950.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Kato, Masato. "Interleukin-10 and Surgery." Critical Care Medicine 29, no. 5 (May 2001): 1093. http://dx.doi.org/10.1097/00003246-200105000-00054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Cohen, Stacey L., Aideen M. Moore, and Wendy E. Ward. "Interleukin-10 Knockout Mouse:." Inflammatory Bowel Diseases 10, no. 5 (September 2004): 557–63. http://dx.doi.org/10.1097/00054725-200409000-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Elson, C. O. "Interleukin-10 and counting …" Gastroenterology 100, no. 6 (June 1991): 1778. http://dx.doi.org/10.1016/0016-5085(91)90687-g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Montero, J. G. "Interleukin 10 and Sepsis." Archives of Surgery 135, no. 7 (July 1, 2000): 875–76. http://dx.doi.org/10.1001/archsurg.135.7.875.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Brennan, F. "Interleukin 10 and arthritis." Rheumatology 38, no. 4 (April 1, 1999): 293–97. http://dx.doi.org/10.1093/rheumatology/38.4.293.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Rennick, Donna, Dan Berg, and Gina Holland. "Interleukin 10: An overview." Progress in Growth Factor Research 4, no. 3 (January 1992): 207–27. http://dx.doi.org/10.1016/0955-2235(92)90020-i.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Sabat, Robert, Gerald Grütz, Katarzyna Warszawska, Stefan Kirsch, Ellen Witte, Kerstin Wolk, and Jens Geginat. "Biology of interleukin-10." Cytokine & Growth Factor Reviews 21, no. 5 (October 2010): 331–44. http://dx.doi.org/10.1016/j.cytogfr.2010.09.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Peng, Hui, Wei Wang, Mo Zhou, Rui Li, Hai-Feng Pan, and Dong-Qing Ye. "Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus." Clinical Rheumatology 32, no. 9 (May 25, 2013): 1255–66. http://dx.doi.org/10.1007/s10067-013-2294-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Peng, Chih-Wen, Hao-Jen Hsu, Chun-Chun Chang, Cheng-Der Liu, Sheng-Feng Pan, and Wei-Han Huang. "Targeting of interleukin-10 receptor by a potential human interleukin-10 peptide efficiently blocks interleukin-10 pathway-dependent cell proliferation." Tzu Chi Medical Journal 32, no. 3 (2020): 245. http://dx.doi.org/10.4103/tcmj.tcmj_237_19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Sotirović, J., A. Perić, D. Vojvodić, N. Baletić, I. Zaletel, I. Stanojević, M. Erdoglija, and M. Milojević. "Serum cytokine profile of laryngeal squamous cell carcinoma patients." Journal of Laryngology & Otology 131, no. 5 (March 15, 2017): 455–61. http://dx.doi.org/10.1017/s0022215117000573.

Full text

Abstract:

AbstractObjectives:This study aimed to evaluate serum cytokine concentrations in healthy individuals and laryngeal squamous cell carcinoma patients.Methods:A total of 59 laryngeal squamous cell carcinoma patients and 44 healthy controls were included. Multiplex analysis of interleukins 2, 4, 5, 6, 10, 12, 13 and 17 and interferon-gamma with respect to the presence of laryngeal carcinoma, tumour–node–metastasis T stage, nodal involvement and larynx subsite was performed.Results:Statistical analysis revealed no difference in serum cytokine levels between patients and healthy controls. The serum interleukin-12 concentration was significantly higher in patients with early (T1–2) than in those with late (T3–4) stage disease and without nodal involvement (p < 0.05). Serum interleukin-10 levels were significantly higher in T3–4 stage than in T1–2 stage patients (p < 0.05). Additionally, serum interleukin 10, 12 and 13 concentrations (p < 0.05) and interleukin-6 concentration (p < 0.01) were significantly higher in patients with T1–2 stage supraglottic vs glottic tumours.Conclusion:Serum cytokines level cannot be used as laryngeal squamous cell carcinoma markers. Progression from T1–2 to T3–4 stage is followed by decreased serum interleukin-12 levels and increased interleukin-10 levels. Nodal involvement is associated with lower serum interleukin-12 levels. In patients with early stage tumours, serum interleukin 6, 10, 12 and 13 concentrations are significantly higher in those with supraglottic vs glottic tumours.

APA, Harvard, Vancouver, ISO, and other styles

36

Wande, I. Nyoman, Endang Retnowati, and Juli Soemarsono. "KADAR INTERLEUKIN 10 (IL-10) MALARIA DAN ANEMIA." INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY 18, no. 1 (October 14, 2016): 4. http://dx.doi.org/10.24293/ijcpml.v18i1.767.

Full text

Abstract:

Anaemia is an important complication of malaria, and its pathogenesis is not well understood. High level of the Th2 cytokine (such as IL-10), which counteract the Th1 cytokine, might prevent the development of severe malarial anaemia. The purpose of this study was to know the comparation between the plasma level of IL-10 in malaria patients with anaemia and without anaemia. The plasma level of IL-10 was examined in 16 malaria patients with anaemia and 16 malaria caused by P. falciparum patients without anaemia samplestaken from patients at the primary health centres in West Lombok and Centre Lombok during March until July 2008. The samples were measured using ELISA. The concentration of haemoglobin (Hb) was measured using hematological analyzer. The anaemia concentration of Hb is <11 g/dL. The results were analyzed using two (2) sample t test with SPSS ver.13.The plasma level of IL-10 in malaria patients caused by P. falciparum with anaemia was 8.81(3.04) [mean(SD)] pg/mL where as the plasma level of IL-10 in malaria patients without anaemia was 47.99(25.26) pg/mL. The mean of IL-10 level in malaria falciparum patients with anaemia was significantly lower than that of malaria patients caused by P. falciparum without anaemia (p=0.000).

APA, Harvard, Vancouver, ISO, and other styles

37

Furukawa, Yutaka, Gerold Becker, Jennifer L. Stinn, Koichi Shimizu, Peter Libby, and Richard N. Mitchell. "Interleukin-10 (IL-10) Augments Allograft Arterial Disease." American Journal of Pathology 155, no. 6 (December 1999): 1929–39. http://dx.doi.org/10.1016/s0002-9440(10)65512-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Salwen, S. A., T. Sato, K. Masuoka, G. Inoue, M. J. Mastrangelo, and D. Berd. "INTERLEUKIN-10 (IL-10) PRODUCTION BY MELANOMA CELLS." Journal of Immunotherapy 18, no. 2 (August 1995): 129. http://dx.doi.org/10.1097/00002371-199508000-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Chukhraiev, A. M., N. M. Agarkov, D. A. Konyaev, E. V. Popova, M. M. Yablokov, and A. S. Kulabukhov. "Infiornativity lacrimal fluid interleukins in diagnostics and development of angle-closure glaucoma in elderly subjects." Russian Journal of Infection and Immunity 10, no. 4 (November 27, 2020): 755–61. http://dx.doi.org/10.15789/2220-7619-iit-1247.

Full text

Abstract:

An increased percentage of the elderly subjects in pattern of contemporary society, along with other causes and risk factors, is accompanied by rise in the incidence of glaucoma. By 2020, according to international studies it is expected that prevalence of glaucoma patients in the world would increase up to 80 million subjects. Among the elderly, glaucoma is a common pathology, which development is associated with local disturbances in interleukin profile. However, the features of the latter in patients with primary closed-angle glaucoma in the elderly were poorly examined. Studies of local interleukin status were conducted mainly in patients with suspected or initial manifestations of primary open-angle glaucoma. The features of lacrimal fluid interleukin shift in a target group of elderly patients suffering from stage II primary closed-angle glaucoma virtually gained no attention. In addition, a limited range of local interleukins in patients with such pathology in previous studies was examined. In addition, informativity of lacrimal fluid interleukins in elderly glaucoma patients was not assessed too based on objective methods. The aim of the current study was to outline features and informativity of local interleukin profile indicators in 58 elderly patients with primary closed-angle glaucoma stage II, aged 60—74 years (main group) and 27 age-matched elderly subjects lacking such pathology. The level of interleukins in the lacrimal fluid was determined with the enzyme immunoassay “Multiscan” analyzer (Finland) by using sandwich ELISA (R&D Diagnostic Inc., USA). Informativity of measuring various interleukins was calculated according to the generally accepted formula. It was found that local interleukin profile in elderly patients with primary closed-angle glaucoma was mainly featured with increased amount of IL-2, IL-17, IL-8, but decreased IL-10. Hence, such local interleukins displayed peak informativity. The data obtained should be used in the diagnostics and treatment of such pathology, as well as of applied importance to unveil novel mechanisms behind development, diagnostics and corroboration for selective immuno-tropic therapy of primary closed-angle glaucoma.

APA, Harvard, Vancouver, ISO, and other styles

40

Bykova, A. Yu, A. A. Kulesh, N. A. Kayleva, E. M. Kuklina, and V. V. Shestakov. "Interrelation of the dynamics of serum concentrations of interleukin-1β, interleukin-6 and interleukin-10 with clinical data in acute ischemic stroke and the strategy of reperfusion therapy." Bulletin of Siberian Medicine 18, no. 4 (January 14, 2020): 16–25. http://dx.doi.org/10.20538/1682-0363-2019-4-16-25.

Full text

Abstract:

Aim. To study the relationship between the dynamics of serum concentrations of interleukin-1β, interleukin-6 and interleukin-10 with clinical data in the acute period of ischemic stroke, and the strategy of reperfusion therapy.Materials and methods. In 28 patients with acute ischemic stroke, half of whom underwent intravenous thrombolysis, the concentration of interleukin-1β, interleukin-6 and interleukin-10 was assessed at admission, on the 3rd and 10th day of the disease.Results. The concentration of interleukin-1β and interleukin-6 decreases during the acute period of stroke. The concentration of interleukin-10 remains unchanged for the first 10 days since the development of stroke. When thrombolysis is performed, there is a more significant decrease in interleukin-1β concentration in the hyperacute period of stroke, whereas in patients without reperfusion there is a decrease in interleukin-6 concentration from 1 to 10 days. The concentration of cytokines is associated with age, lipid spectrum, severity of carotid atherosclerosis, myocardial hypertrophy and injection fraction of the heart. Only in the subgroup of thrombolysis, correlations of cytokine concentrations with systolic blood pressure at admission, hemoglobin concentration, total cholesterol and high-density lipoproteins, hematocrit, degree of stenosis of the contralateral carotid artery, injection fraction and the number of antihypertensive drugs prescribed in the hospital were recorded. The concentration of interleukin-6 at day 10 is associated with the severity of stroke at admission, and the level of IL-10 on day 3 of the disease, with the mobility of patients at discharge.Conclusions. In the hyperacute period of stroke, there is a decrease in the pro-inflammatory activity of blood serum, more pronounced in patients undergoing systemic thrombolysis. Concentrations of interleukin1β, interleukin-6 and interleukin-10 are associated with a wide range of parameters characterizing the cardiovascular and functional status, and the pattern of these associations differs depending on the reperfusion therapy strategy.

APA, Harvard, Vancouver, ISO, and other styles

41

Brouet, J. C., and Y. Levy. "Interleukine 10 et cellules B centrofolliculaires." médecine/sciences 10, no. 6-7 (1994): 726. http://dx.doi.org/10.4267/10608/2696.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Tedgui, Alain, and Ziad Mallat. "Interleukine-10 : une cytokine anti-athérogène ?" Pathologie Biologie 49, no. 2 (January 2001): 107–8. http://dx.doi.org/10.1016/s0369-8114(00)00013-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Kuryltsiv, Nadiya B., and Kateryna M. Halei. "THE ROLE OF INTERLEUKINS AND THEIR INHIBITORS IN THE DEVELOPMENT OF AUTOIMMUNE UVEITIS." Wiadomości Lekarskie 72, no. 4 (2019): 716–22. http://dx.doi.org/10.36740/wlek201904141.

Full text

Abstract:

Introduction: Autoimmune uveitis (AU) is an inflammation of the uvea due to an autoimmune reaction to self-antigens. There are no standardized treatment protocols for AU. A new class of drugs called biologics, that target the various mediators of the inflammation cascade, may potentially provide more effective and less toxic corticosteroids treatment of AU. The aim: The aim of this review was to make the evaluatation of the interleukins influence on intraocular inflammation in available literature and summarize the expediency of using anti-interleukins agent in case of AU. Material and methods: This article is a review and summary of the up-to-date results of pivotal experimental and clinical trials targeting the Interleukins (IL), including IL-6, IL-10, IL-17, IL-22, IL-23, and tumor necrosis factor alpha (TNF-α). Also reviews focus on the potential use of anti-interleukin therapy for the treatment of autoimmune diseases (AD). Conclusions: AU is an inflammation of the uvea due to an autoimmune reaction to self-antigens. The most important IL in the pathogenesis of AU are IL-6, IL-10, IL-17, IL-22, IL-23 and TNF-α. Anti-interleukin therapy is partially described. Future randomized controlled trials are urgently needed to be conduct.

APA, Harvard, Vancouver, ISO, and other styles

44

Yoon, S. H., M. E. Kim, H. Y. Kim, J. S. Lee, and C. H. Jang. "Inflammatory cytokines and mononuclear cells in sudden sensorineural hearing loss." Journal of Laryngology & Otology 133, no. 2 (February 2019): 95–101. http://dx.doi.org/10.1017/s0022215119000100.

Full text

Abstract:

AbstractObjectiveThis study evaluated tumour necrosis factor-α, interleukins 10 and 12, and interferon-γ levels, peripheral blood mononuclear cells, and clusters of differentiation 17c and 86 expression in unilateral sudden sensorineural hearing loss.MethodsTwenty-four patients with unilateral sudden sensorineural hearing loss, and 24 individuals with normal hearing and no history of sudden sensorineural hearing loss (who were attending the clinic for other problems), were enrolled. Peripheral blood mononuclear cells, and clusters of differentiation 11c and 86 were isolated and analysed. Plasma and supernatant levels of tumour necrosis factor-α, interferon-γ, and interleukins 10 and 12 were measured.ResultsThere were no significant differences with respect to age and gender. Monocyte population, mean tumour necrosis factor-α level and cluster of differentiation 86 expression were significantly increased in the study group compared to the control group. However, interferon-γ and interleukin 12 levels were significantly decreased. The difference in mean interleukin 10 level was not significant.ConclusionIncreases in tumour necrosis factor-α level and monocyte population might play critical roles in sudden sensorineural hearing loss. This warrants detailed investigation and further studies on the role of dendritic cells in sudden sensorineural hearing loss.

APA, Harvard, Vancouver, ISO, and other styles

45

Benjamin, David, Chanun D. Park, and Venkatanarayanan Sharma. "Human B Cell Interleukin 10." Leukemia & Lymphoma 12, no. 3-4 (January 1994): 205–9. http://dx.doi.org/10.3109/10428199409059591.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Garofalo, Roberto, Sadhana Chheda, Fang Mei, Kimberly H. Palkowetz, Helen E. Rudloff, Frank C. Schmalstieg, David K. Rassin, and Armond S. Goldman. "Interleukin-10 in Human Milk." Pediatric Research 37, no. 4 (April 1995): 444–49. http://dx.doi.org/10.1203/00006450-199504000-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Freer, Giulia. "Interleukin 10 in Antiviral Responses." Current Immunology Reviews 12, no. 1 (March 30, 2016): 20–26. http://dx.doi.org/10.2174/1573395512666151216210559.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Cihakova, Daniela. "Interleukin-10 stiffens the heart." Journal of Experimental Medicine 215, no. 2 (January 18, 2018): 379–81. http://dx.doi.org/10.1084/jem.20180049.

Full text

Abstract:

Cardiac-resident macrophages are a diverse population of cells that have a critical role in the pathogenesis of heart failure. A new understanding of communication between macrophages and cardiac fibroblasts could lead to novel therapeutic strategies for heart failure with preserved ejection function.

APA, Harvard, Vancouver, ISO, and other styles

49

Marchant, A., M. Goldman, J. Devière, B. Byl, J. L. Vincent, and D. De Groote. "Interleukin-10 production during septicaemia." Lancet 343, no. 8899 (March 1994): 707–8. http://dx.doi.org/10.1016/s0140-6736(94)91584-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Moore, Kevin W., Rene de Waal Malefyt, Robert L. Coffman, and Anne O'Garra. "INTERLEUKIN-10AND THEINTERLEUKIN-10 RECEPTOR." Annual Review of Immunology 19, no. 1 (April 2001): 683–765. http://dx.doi.org/10.1146/annurev.immunol.19.1.683.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Interleukines 10'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles